New Delhi: Israel has isolated a key coronavirus antibody at its primary biological research centre, Defence Minister Naftali Bennett said Monday. He called it a “significant breakthrough” towards a possible treatment for Covid-19.
In an official statement, Bennet claimed that the “monoclonal neutralising antibody” developed by the Israel Institute for Biological Research (IIBR) “attacks the virus and neutralizes it” inside the virus carrier’s body.
Monoclonal antibodies, as the name suggests, are cloned from a single recovered cell. Thus, they are much easier to create and use, as opposed to polyclonal antibodies which will have to be derived from multiple cells.
In typical antibody vaccines, neutralisation occurs when the laboratory-developed antibodies mimic the body’s natural immune response and attack the virus when exposed to it.
IIBR completes development phase
According to the Jerusalem Post, IIBR has completed the development phase of the antibody formula and is now looking to manufacture it.
The statement quotes IIBR Director Shmuel Shapira as saying the antibody formula was being patented, after which an international manufacturer would be sought to mass-produce it.
We are deeply grateful to our readers & viewers for their time, trust and subscriptions.
Quality journalism is expensive and needs readers to pay for it. Your support will define our work and ThePrint’s future.
The IIBR, a secretive research unit working directly under the office of Israel’s Prime Minister, has not released any further information about the vaccine itself. If effective, the development of an antibody is very promising, and this vaccine would join several other candidates that are already being touted as potential vaccines for Covid-19.
However, most potential vaccines are currently in human trials. Though Shapira said mass production is about to begin, it is unclear whether the vaccine has been tested for safety or efficacy on humans.
IIBR is a unit that works to counter biological threats against Israel and has been taking the lead in order to develop a treatment and vaccine for the coronavirus, including plasma collection that includes the testing of blood from those who recovered from Covid-19.
Israel was one of the first countries to close its borders and impose increasingly stringent restrictions on movement to arrest the spread of the novel coronavirus. It has reported 16,246 cases and 235 deaths due to Covid-19.
With inputs from Sandhya Ramesh
News media is in a crisis & only you can fix it
You are reading this because you value good, intelligent and objective journalism. We thank you for your time and your trust.
You also know that the news media is facing an unprecedented crisis. It is likely that you are also hearing of the brutal layoffs and pay-cuts hitting the industry. There are many reasons why the media’s economics is broken. But a big one is that good people are not yet paying enough for good journalism.
We have a newsroom filled with talented young reporters. We also have the country’s most robust editing and fact-checking team, finest news photographers and video professionals. We are building India’s most ambitious and energetic news platform. And we aren’t even three yet.
At ThePrint, we invest in quality journalists. We pay them fairly and on time even in this difficult period. As you may have noticed, we do not flinch from spending whatever it takes to make sure our reporters reach where the story is. Our stellar coronavirus coverage is a good example. You can check some of it here.
This comes with a sizable cost. For us to continue bringing quality journalism, we need readers like you to pay for it. Because the advertising market is broken too.
If you think we deserve your support, do join us in this endeavour to strengthen fair, free, courageous, and questioning journalism, please click on the link below. Your support will define our journalism, and ThePrint’s future. It will take just a few seconds of your time.